Circassia plummets after Phase III cat allergy failure

Circassia Pharmaceuticals plc (LSE:CIR) fell 179.30p (66%) to 91p and shed L510.8 million in market cap Monday after its Cat-SPIRE missed the primary endpoint in the Phase III

Read the full 281 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE